
Verastem Oncology (NASDAQ:VSTM) brought in sales totaling $2.60 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.92%, resulting in a loss of $16.96 million. In Q4, Verastem Oncology brought in $545.00 thousand in sales but lost $16.48 million in earnings.